CD8A and neoplasm: The efficacy of the rF9R/rE7m complex was subsequently tested in tumor models to assess CD8<sup>+</sup> T-cell activation and tumor regression.<h4>Results</h4>The rF9R protein successfully bound peptides and antigens to form stable complexes, significantly enhancing antigen delivery and immune activation.